Stay updated with breaking news from Kodiak Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Kodiak Sciences will abandon further development of its lead drug to treat a type of eye disease after it failed in two late-stage studies, the company said on Monday, sending its shares tumbling more...
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to...
Kodiak Sciences Inc. (KOD) reported topline results from three Phase 3 studies of tarcocimab tedromer, a antibody biopolymer conjugate. The DAYLIGHT study evaluating the efficacy and safety of a high intensity dosing regimen of tarcocimab tedromer in 557 treatment-naïve subjects with wet Age-Related Macular Degeneration met the primary endpoint of non-inferior visual acuity gains for tarcocimab dosed monthly compared to aflibercept dosed every 8 weeks following 3 monthly loading doses.
-- Kodiak Sciences has an average rating of outperform and price targets ranging from $5 to $24, according to analysts polled by Capital IQ. Price: 3.04, Change: -4.25, Percent Change: -58.30 ...
Kodiak Sciences shares fell by more than 45% after the biopharmaceutical company announced that it was discontinuing its tarcocimab program for eye...